Ziconotide - Jazz Pharmaceuticals/RIEMSER Arzeneimittel

Drug Profile

Ziconotide - Jazz Pharmaceuticals/RIEMSER Arzeneimittel

Alternative Names: CI 1009; MVIIA; Prialt; SNX 111; SNX 194; Ziconotide acetate - Jazz Pharmaceuticals/RIEMSER Arzeneimittel

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Pharmaceuticals
  • Developer Eisai Co Ltd; Elan Pharmaceuticals; Jazz Pharmaceuticals plc; RIEMSER Arzneimittel
  • Class Conotoxins; Neuroprotectants; Non-opioid analgesics; Peptides
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Discontinued Craniocerebral trauma; Stroke

Most Recent Events

  • 02 Jul 2018 Jazz Pharamceuticals enters into a definetive agreement to sell rights related to ziconotide intrathecal infusion to TerSera Therapeutics
  • 23 Apr 2018 RIEMSER Arzneimittel acquires Ziconotide from Eisai Co Ltd in Europe
  • 18 Jan 2012 Azur Pharma has merged with Jazz Pharmaceuticals Inc to form Jazz Pharmaceuticals plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top